This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...

Alzheimer’s researchers have long wished for better mouse models. That is now coming true. Scientists at the Jackson Laboratory in Bar Harbor, Maine, are cranking out numerous lines that express ...

In a draft decision, the CMS proposed covering Aduhelm only in clinical trials. Most Alzheimer’s researchers support the proposal. Some challenged its practicality. The manufacturers of the other anti ...

Will Biogen’s aducanumab become the first drug approved to slow progression of Alzheimer’s disease? Biogen’s licensing application for the biologic ran into headwinds at a U.S. Food and Drug ...

Buoyed by data crediting amyloid removal with ever-so-slightly slowed cognitive decline, many scientists are now optimistic about the prospects for anti-amyloid immunotherapy. Four “-mabs”—of the ...

Not so long ago, a blood test for Alzheimer’s disease seemed a pipe dream. Now, after years of study, the field is awash with sensitive assays that signal the proteopathic culprits Aβ and tau ...

Is idiopathic Alzheimer’s more than one disease? And is there even such a thing as “typical” AD? Given the heterogeneity in clinical presentation and pathology, some scientists have suggested as much ...

On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...

The top-line results last September from Eisai’s Phase 3 trial of the anti-amyloid antibody lecanemab galvanized the field, but scientists said they needed to see the data before passing judgement.

In Europe and the U.S., proportionately fewer people are developing dementia now than in the past. Is this driven by less-prevalent Alzheimer's disease pathology? No, say researchers led by Francine ...